RXi Pharmaceuticals said it will split into two public firms. The company renamed itself Galena Biopharma to specialize in targeted cancer drugs and will spin off RXi this year to continue working on RNAi-based therapies.
Published in Brief:
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||